

ASSIGNMENT

We, the undersigned,

PARK, Minhyung; 303ho, 8, Jeongjo-ro 535beon-gil, Gwonseon-gu, Suwon-si Gyeonggi-do 16587 (KR)

HWANG, On; 107-902, 17, Suji-ro, Suji-gu Yongin-si Gyeonggi-do 16863 (KR)

HA, Songyi; 107-902, 17, Suji-ro, Suji-gu Yongin-si Gyeonggi-do 16863 (KR)

KIM, Gyoungwon; 110-1003, 283, Dongbaekjukjeon-daero, Giheung-gu Yongin-si Gyeonggi-do 16995 (KR)

KIM, Hoe Sung; 302ho, 288, Pogok-ro, Pogok-eup, Cheoin-gu Yongin-si Gyeonggi-do 17028 (KR)

CHO, Sangeun; 440-2102, 87, Jukjeon-ro, Suji-gu Yongin-si Gyeonggi-do 16899 (KR)

KIM, Gwan Young; 201-3304, 40-18, Gogi-ro 45beon-gil, Suji-gu Yongin-si Gyeonggi-do 16824 (KR)

which here and after is referred as the ASSIGNOR,

By these presents declare under oath to be the solo and true inventor/s of the invention entitled: "PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN AND METFORMIN", identified by international application number PCT/KR2023/021876

And,

DAEWOONG PHARMACEUTICAL CO., LTD., a corporation organized and existing under the law of South Korea, having its domiciled in 35-14, Jeyakgongdan 4-gil, Hyangnam-eup Hwaseong-si Gyeonggi-do 18623 (KR) and represented by (individual's name) Taeheon Kim acting a his (her) (job title) IP manager, which here and after is named as ASSIGNEE,

Both, ASSIGNOR and ASSIGNEE have agreed the following:

To ASSIGN from the ASIGNOR to the ASSIGNEE the Industrial Property Rights related to the patent application entitled "PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN AND METFORMIN".

Given on June 9, 2025 in Seoul, South Korea

Park, minhyung
ASSIGNOR
PARK, Minhyung

Hwang on
ASSIGNOR
HWANG, On

CESION

Nosotros, abajo firmando/s,

PARK, Minhyung; 303ho, 8, Jeongjo-ro 535beon-gil, Gwonseon-gu, Suwon-si Gyeonggi-do 16587 (KR)

HWANG, On; 107-902, 17, Suji-ro, Suji-gu Yongin-si Gyeonggi-do 16863 (KR)

HA, Songyi; 107-902, 17, Suji-ro, Suji-gu Yongin-si Gyeonggi-do 16863 (KR)

KIM, Gyoungwon; 110-1003, 283, Dongbaekjukjeon-daero, Giheung-gu Yongin-si Gyeonggi-do 16995 (KR)

KIM, Hoe Sung; 302ho, 288, Pogok-ro, Pogok-eup, Cheoin-gu Yongin-si Gyeonggi-do 17028 (KR)

CHO, Sangeun; 440-2102, 87, Jukjeon-ro, Suji-gu Yongin-si Gyeonggi-do 16899 (KR)

KIM, Gwan Young; 201-3304, 40-18, Gogi-ro 45beon-gil, Suji-gu Yongin-si Gyeonggi-do 16824 (KR)

quien en adelante será el CEDENTE,

Por el presente documento declaramos bajo juramento ser el/los único/s y verdadero/s inventor/es de la invención titulada: "COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE ENAVOGLIFLOZINA Y METFORMINA", identificada mediante la solicitud internacional número PCT/KR2023/021876

Y,

DAEWOONG PHARMACEUTICAL CO., LTD., una sociedad debidamente constituida y existente bajo las leyes de Corea del Sur, con domicilio en 35-14, Jeyakgongdan 4-gil, Hyangnam-eup Hwaseong-si Gyeonggi-do 18623 (KR) y representada por (nombre) Taeheon Kim quien actúa como (título) IP manager, quien en adelante será el CESIONARIO,

Ambos, CEDENTE y CESIONARIO han acordado lo siguiente:

CEDER del CEDENTE al CESIONARIO los derechos de propiedad Industrial relativos a la solicitud de patente titulada "COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE ENAVOGLIFLOZINA Y METFORMINA".

Dado en June 9, 2025 el Seoul, South Korea

Park minhyung
CEDENTE
PARK, Minhyung

Hwang on
CEDENTE
HWANG, On

Ha Songyi

ASSIGNOR
HA, Songyi

Kim, Gyoungwon

ASSIGNOR
KIM, Gyoungwon

Kim Hoe Sung

ASSIGNOR
KIM, Hoe Sung

Cho. Sangeun

ASSIGNOR
CHO, Sangeun

Kim Gwan Young

ASSIGNOR
KIM, Gwan Young

Kim Tae-heon

ASSIGNEE
DAEWOONG PHARMACEUTICAL CO., LTD.



Ha Songyi

CEDENTE
HA, Songyi

Kim, Gyoungwon

CEDENTE
KIM, Gyoungwon

Kim Hoe Sung

CEDENTE
KIM, Hoe Sung

Cho. Sangeun

CEDENTE
CHO, Sangeun

Kim Gwan Young

CEDENTE
KIM, Gwan Young

Kim Tae-heon

CESIONARIO
DAEWOONG PHARMACEUTICAL CO., LTD.

